[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 449,454,464
  • Shares Outstanding, K 1,766,793
  • Annual Sales, $ 61,160 M
  • Annual Income, $ 4,226 M
  • EBIT $ 15,332 M
  • EBITDA $ 24,318 M
  • 60-Month Beta 0.30
  • Price/Sales 7.05
  • Price/Cash Flow 16.12
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 31.15% (+0.07%)
  • Historical Volatility 33.91%
  • IV Percentile 87%
  • IV Rank 75.35%
  • IV High 35.30% on 04/27/26
  • IV Low 18.46% on 08/22/25
  • Expected Move (DTE 6) 5.80 (2.28%)
  • Put/Call Vol Ratio 0.40
  • Today's Volume 23,328
  • Volume Avg (30-Day) 22,357
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 263,851
  • Open Int (30-Day) 247,623
  • Expected Range 248.69 to 260.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $3.66
  • Number of Estimates 5
  • High Estimate $3.81
  • Low Estimate $3.59
  • Prior Year $2.97
  • Growth Rate Est. (year over year) +23.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
215.37 +18.16%
on 06/18/26
261.64 -2.73%
on 07/02/26
+33.26 (+15.03%)
since 06/17/26
3-Month
190.75 +33.42%
on 04/29/26
261.64 -2.73%
on 07/02/26
+46.11 (+22.13%)
since 04/17/26
52-Week
184.63 +37.84%
on 07/21/25
261.64 -2.73%
on 07/02/26
+63.09 (+32.96%)
since 07/17/25

Most Recent Stories

More News
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

NORTH CHICAGO, Ill. , July 17, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the European Commission has approved Boey ®  (trenibotulinumtoxinE) in Europe,...

ABBV : 254.49 (+0.04%)
MoneyMasters Podcast: Where to Invest NOW in AI, Biotech, Small Caps, & Gold!

In this timely and actionable episode, Jeffrey Hirsch, John McCamant, and Luke Lloyd discuss the best profit opportunities for the second half of 2026.

GWRE : 150.02 (+0.75%)
CLDX : 35.35 (-0.14%)
PGEN : 4.95 (unch)
NVO : 50.32 (-2.25%)
AKAM : 120.19 (+1.16%)
SNEX : 102.99 (-7.12%)
ORCL : 126.41 (+1.77%)
ABBV : 254.49 (+0.04%)
GDXJ : 92.20 (-0.49%)
RSP : 213.37 (-0.79%)
VKTX : 37.08 (+1.95%)
LLY : 1,179.11 (+0.85%)
SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

IRVINE, Calif. , July 14, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, is proud to announce SkinMedica's expanded commitment to regenerative science, advancing investments...

ABBV : 254.49 (+0.04%)
5 Dividend Kings to Buy in July with Irristable Value and Yield

Five Dividend Kings—Procter & Gamble, Hormel, Stanley Black & Decker, Genuine Parts and Lowe's—trade at discounted valuations, offering attractive yields despite near-term business headwinds.

HRL : 25.39 (-1.24%)
ABT : 100.68 (+1.87%)
ORLY : 86.05 (-0.23%)
LOW : 208.73 (-3.44%)
SWK : 90.17 (-1.25%)
AZO : 3,046.44 (-0.51%)
PG : 149.98 (-1.00%)
GPC : 124.82 (-0.67%)
ABBV : 254.49 (+0.04%)
AbbVie Earnings Preview: What to Expect

AbbVie will release its second-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.

XLV : 161.09 (-0.44%)
$SPX : 7,457.69 (-1.01%)
APOG : 41.03 (-0.46%)
ABBV : 254.49 (+0.04%)
AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years

While one continues reinvesting for growth, the other has rewarded shareholders for 54 years in a row.

APGE : 134.00 (-0.06%)
LLY : 1,179.11 (+0.85%)
ABBV : 254.49 (+0.04%)
Abivax: Wall Street Catches Up to the Data

Abivax stock surged over 40% after positive Phase 3 data on ulcerative colitis drug Obefazimod and a $920 million share offering that underwriters fully exercised, signaling strong institutional demand....

ABBV : 254.49 (+0.04%)
ABVX : 136.65 (-0.81%)
3 Market-Beating Stocks Worth Investigating

3 Market-Beating Stocks Worth Investigating

WTS : 346.43 (-1.97%)
SFM : 75.78 (+2.86%)
ABBV : 254.49 (+0.04%)
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill. , July 6, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY ® (epcoritamab) in combination...

ABBV : 254.49 (+0.04%)
Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks

Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks

ABBV : 254.49 (+0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 265.54
2nd Resistance Point 263.25
1st Resistance Point 258.87
Last Price 254.49
1st Support Level 252.20
2nd Support Level 249.91
3rd Support Level 245.53

See More

52-Week High 261.64
Last Price 254.49
Fibonacci 61.8% 232.22
Fibonacci 50% 223.13
Fibonacci 38.2% 214.05
52-Week Low 184.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.